Latest market headlines for ZIMLAB on Terminal.
04-Nov-2026 14:37:54
• Revenue up 18.9% at ₹105.45 Cr (YOY), up 12.0% (QOQ). • Ebitda at ₹7.73 Cr v ₹7.80 Cr (YOY), ₹3.44 Cr (QOQ). • Margins 7.3% v 8.8% (YOY), 3.7% (QOQ).
04-Nov-2026 14:37:18
REVENUE UP 19% AT ₹105 CR (YOY), UP 12% (QOQ) EBITDA DOWN 6% AT ₹5 CR (YOY), UP 121% (QOQ) MARGINS AT 5.1% VS 6.5% (YOY), 2.6% (QOQ)
16-Oct-2026 12:51:36
• TGA GMP Certificate of Compliance issued 15 October 2026 for manufacturing facility at B-21/22, MIDC Area, Kalmeshwar, Nagpur • Scope covers non-sterile fini…
08-Oct-2026 20:22:05
• CARE Ratings reaffirmed long-term bank facilities at CARE BBB; outlook revised to Negative from Stable • Long-term bank facilities covered by the action aggr…
18-Sept-2026 08:13:27
• ZIM Laboratories SpA incorporated in Santiago, Republic of Chile. • The subsidiary is a Wholly Owned Subsidiary (WOS). • Objective is expansion and developme…
15-Sept-2026 19:53:15
• ZIM Laboratories Limited FZE (ZIM FZE), a wholly owned subsidiary, has completed the investment of the entire approved amount in the share capital of ZIM Sci…